Elsevier and Federation of Biochemical Societies Launch New Journal: FEBS Open Bio
Amsterdam, December 14, 2011 – Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the Federation of Biochemical Societies (FEBS) announced today the launch of FEBS Open Bio, an open access journal. The journal is dedicated to publishing articles across the molecular and cellular life sciences in both health and disease.
In launching this new journal, FEBS and Elsevier serve authors who have an interest in a fast publishing process. The journal is open to direct submissions of novel findings. It is also open to the transfer of articles submitted to existing FEBS publications (FEBS Letters, FEBS Journal and Molecular Oncology), which have been judged as sound and a contribution to knowledge, but do not meet the criteria set by the editors for publication in these journals. These manuscripts can now proceed for publication in FEBS Open Bio with their original reviewer reports, without the need to resubmit or reformat the manuscript.
Felix Goñi, Chairman of the FEBS publication committee says, “As a society aimed at advancing science we do understand that the needs of the community change over time. Launching FEBS Open Bio is the result of listening to the scientists we serve. We are very happy that many of the editors of existing FEBS journals are actively supporting this new launch and have joined the editorial board of FEBS Open Bio.”
Carl Schwarz, Publishing Director Elsevier Life Sciences said, “We are delighted that we have been able to expand our collaboration with FEBS by launching a new journal that will certainly benefit the scientific community. The launch of FEBS Open Bio is yet another milestone in our continuous collaboration with FEBS.”
# # #
Founded on the 1st of January 1964, the Federation of Biochemical Societies (FEBS) is a not-for-profit charity and is one of the largest organizations in European life sciences, with nearly 40.000 members distributed among 36 Constituent Societies and 7 Associated Member Societies in 43 countries. FEBS seeks to promote, encourage and support biochemistry, molecular cell biology and molecular biophysics throughout Europe in a variety of ways, such as offering courses, fellowships, awards and prizes. FEBS publishes journals and organizes an annual congress. Go to: www.febs.org
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
Gwen van der Heide
+ 31 20 485 2594